Single ascending dose of orally administered capsule(s) NPT200-11 vs placebo: 15, 30, 60,120, 240, 360 and 480 mg dose.
PRIMARY OUTCOME MEASURE: Safety, including adverse events, physical examinations, ECGs, clinical laboratory tests. Time Frame: Screening (28 days prior to dosing) through Day 7. SECONDARY OUTCOME MEASURES: To possibly determine the maximally tolerated dose (MTD) of orally administered NPT200-11 in healthy subjects. The number of participants with unacceptable toxicities at each dose level will determine the maximally tolerated dose.
An early phase SAD study was completed but the data have not been published and no information on future drug development are available.